MARKET

NEO

NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.09
-0.97
-2.31%
After Hours: 41.08 -0.01 -0.02% 19:21 05/07 EDT
OPEN
42.90
PREV CLOSE
42.06
HIGH
43.93
LOW
40.92
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
61.57
52 WEEK LOW
25.19
MARKET CAP
4.81B
P/E (TTM)
1284.06
1D
5D
1M
3M
1Y
5Y
8-K: NEOGENOMICS INC
(EDGAR Online via COMTEX) -- 0001077183FALSE00010771832021-05-052021-05-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
10-Q: NEOGENOMICS INC
(EDGAR Online via COMTEX) -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS NeoGenomics, Inc., a Nevada corporation,...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
--Needham Adjusts NeoGenomics' Price Target to $55 From $65; Buy Rating Kept
MT Newswires · 3d ago
NeoGenomics (NEO) Receives a Buy from Needham
Needham analyst Michael Matson reiterated a Buy rating on NeoGenomics (NEO) today and set a price target of $55.00. The company's shares closed last
SmarterAnalyst · 3d ago
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 3d ago
BRIEF-Neogenomics Says Quarterly Consolidated Revenue Increased 9%
reuters.com · 3d ago
Recap: NeoGenomics Q1 Earnings
  Shares of NeoGenomics (NASDAQ:NEO) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 100.00% year over year to ($0.04), which missed the estimate of $0.01.
Benzinga · 3d ago
BRIEF-Inivata To Be Acquired By NeoGenomics
reuters.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEO. Analyze the recent business situations of Neogenomics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEO stock price target is 60.00 with a high estimate of 65.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 441
Institutional Holdings: 116.09M
% Owned: 99.18%
Shares Outstanding: 117.05M
TypeInstitutionsShares
Increased
102
5.94M
New
68
1.09M
Decreased
114
4.58M
Sold Out
19
425.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.41%
Healthcare Providers & Services
+1.36%
Key Executives
Chairman/Executive Director
Douglas VanOort
President
George Cardoza
Chief Executive Officer
Mark Mallon
Chief Financial Officer
Kathryn McKenzie
Corporate Executive
Robert Shovlin
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Information Officer
Steven Ross
Chief Compliance Officer
Stephanie Bywater
Vice President
Jennifer Balliet
General Counsel/Secretary
Denise Pedulla
Director of Investor Relations/IR Contact Officer
William Bonello
Other
Douglas Brown
Lead Director/Independent Director
Lynn Tetrault
Director
Steven Jones
Director
Rachel Stahler
Independent Director
Bruce Crowther
Independent Director
Alison Hannah
Independent Director
Raymond Hipp
Independent Director
Kevin Johnson
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
No Data
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.